ConcertAI Appoints Warren A. Whyte, PhD, Vice President of Strategic Partnerships & Customer Success

An RWE innovator positions company for pharma- and patient-centered partnerships with its leading oncology Real-World Data and eurekaHealth family of AI-enabled technologies

Boston, MA, May 6, 2020 – ConcertAI, the leader in Real-World Evidence (RWE) and AI solutions for the life sciences and healthcare industries, is pleased to welcome Warren A. Whyte, PhD, as Vice President of Strategic Partnerships and Customer Success.

Dr. Whyte joins ConcertAI after spending the last several years at Accenture, where he led the strategic delivery of RWE offerings for leading drug and medical device companies across medical affairs, R&D and commercial functions. Prior to Accenture, Dr. Whyte consulted for several biopharmaceutical companies, and led research in genomics and molecular biology that preceded the creation of Syros Pharmaceuticals, a venture-backed gene therapy company. Dr. Whyte has published in several peer-reviewed scientific journals. He has a BS in molecular and cell biology from Cornell University and a PhD in genomics from MIT.

“I am thrilled to welcome Warren in the midst of the most profound changes in the healthcare system of our lifetime,” said Jeff Elton, PhD and CEO of ConcertAI. “His experience advancing novel RWE solutions, founded on both data and RWE technologies, will accelerate our mission to bring the most precise and innovative therapeutics to patients faster and more confidently.”

“I’m excited to join the ConcertAI team during this unprecedented time,” said Dr. Whyte, who will oversee customer delivery of ConcertAI’s data and technology products. “I’m looking forward to advancing our partnerships with life sciences and healthcare customers in delivering truly innovative data and AI-powered medicines to patients.”